肺胀气虚颗粒用于治疗COPD稳定期肺肾气虚型患者的临床疗效分析  

Analysis of the clinical effect of Feizhang Qixu particle in treating patients with lung and kidney qi deficiency in stable COPD

作　　者：李冀 Li Ji(Hospital of Traditional Chinese Medicine,Ningxia Hui Autonomous Region,Yinchuan,Ningxia 750021,China)

机构地区：[1]宁夏回族自治区中医医院,宁夏银川750021

出　　处：《首都食品与医药》2024年第23期163-166,共4页Capital Food Medicine

基　　金：宁夏医科大学科学研究资助项目研究计划(编号:XM2022075)。

摘　　要：目的 探讨肺胀气虚颗粒用于治疗COPD稳定期肺肾气虚型患者的临床疗效.方法 本试验研究对象来自2023年1月-2023年12月在我院接受治疗的60例COPD稳定期肺肾气虚型患者,随机分为试验组(30例)和对照组(30例),对照组采用沙美特罗替卡松吸入粉雾剂治疗,试验组采用肺胀气虚颗粒治疗,对比分析两组效果.结果 两组治疗总有效率比较,差异不显著(P>0.05).治疗前,两组中医证候积分、CAT评分比较,差异不显著(P>0.05),经治疗,两组中医证候积分、CAT评分均得到显著改善(P<0.05);治疗后,试验组中医证候积分、CAT评分均显著优于对照组(P<0.05).治疗前,两组FEV1、FEV1%、FENO、PaO2比较,差异不显著(P>0.05),经治疗,两组FEV1、FEV1%、FENO、PaO2均得到显著改善(P<0.05);治疗后,两组FEV1、FEV1%、FENO、PaO2比较,差异显著(P<0.05).试验组不良反应发生率显著低于对照组(P<0.05).结论 肺胀气虚颗粒用于治疗COPD稳定期肺肾气虚型患者疗效与西药相当,但能更好地改善患者生活质量,显著降低不良反应发生率,可在临床借鉴、推广.Objective To investigate the clinical effect of Feizhang Qixu particle in treating patients with pulmonary and kidney qi deficiency in stable COPD.Methods The subjects of this study were 60 patients with pulmonary and kidney qi deficiency in stable COPD who received treatment in our hospital from January 2023 to December 2023,and were randomly divided into experimental group and control group,with 30 cases in each group;the control group was treated with salmeterol and ticasone inhalation powder,and the experimental group was treated with Feizhang Qixu particle.The effects of the two groups were compared and analyzed.Results There was no significant difference in the total effective rate between the two groups(P>0.05).Before treatment,there were no significant differences in TCM syndrome score and CAT score between the two groups(P>0.05).After treatment,TCM syndrome score and CAT score were significantly improved between the two groups(P<0.05).After treatment,TCM syndrome scores and CAT scores of experimental group were significantly better than those of control group(P<0.05).There were no significant differences in FEV1,FEV1%,FENO and PaO2 between the two groups before treatment(P>0.05),but FEV1,FEV1%,FENO and PaO2 were significantly improved after treatment(P<0.05).There were significant differences in FEV1,FEV1%,FENO and PaO2 between the two groups after treatment(P<0.05).The incidence of adverse reactions in experimental group was significantly lower than that in control group(P<0.05).Conclusion The therapeutic effect of Feizhang Qixu particle in treating COPD patients in stable stage is comparable to that of western medicine,but it can better improve the quality of life of patients and significantly reduce the occurrence of adverse reactions,which can be used for clinical reference and promotion.

关 键 词：COPD 稳定期 肺肾气虚型 肺胀气虚颗粒 

分 类 号：R563.9[医药卫生—呼吸系统]